Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 3
1(20.0%)
Phase 2
1(20.0%)
5Total
Phase 1(3)
Phase 3(1)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07629544Phase 3Not Yet Recruiting

A Study of DA-302168S in Participants With Overweight/Obesity

Role: lead

NCT06953063Phase 2Completed

A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects

Role: lead

NCT06541730Phase 1Completed

A Study Evulating DA-302168S Tablets in Overweight/Obese Subjects

Role: lead

NCT06534346Phase 1Completed

The Food Effect on Pharmacokinetics of DA-302168S

Role: lead

NCT06534320Phase 1Completed

Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of DA-302168S Tablets

Role: lead

All 5 trials loaded